130 related articles for article (PubMed ID: 35264439)
1. Spatial profiling reveals association between WNT pathway activation and T-cell exclusion in acquired resistance of synovial sarcoma to NY-ESO-1 transgenic T-cell therapy.
Campbell KM; Thaker M; Medina E; Kalbasi A; Singh A; Ribas A; Nowicki TS
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35264439
[TBL] [Abstract][Full Text] [Related]
2. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.
Ramachandran I; Lowther DE; Dryer-Minnerly R; Wang R; Fayngerts S; Nunez D; Betts G; Bath N; Tipping AJ; Melchiori L; Navenot JM; Glod J; Mackall CL; D'Angelo SP; Araujo DM; Chow WA; Demetri GD; Druta M; Van Tine BA; Grupp SA; Abdul Razak AR; Wilky B; Iyengar M; Trivedi T; Winkle EV; Chagin K; Amado R; Binder GK; Basu S
J Immunother Cancer; 2019 Oct; 7(1):276. PubMed ID: 31651363
[TBL] [Abstract][Full Text] [Related]
3. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.
Robbins PF; Kassim SH; Tran TL; Crystal JS; Morgan RA; Feldman SA; Yang JC; Dudley ME; Wunderlich JR; Sherry RM; Kammula US; Hughes MS; Restifo NP; Raffeld M; Lee CC; Li YF; El-Gamil M; Rosenberg SA
Clin Cancer Res; 2015 Mar; 21(5):1019-27. PubMed ID: 25538264
[TBL] [Abstract][Full Text] [Related]
4. Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor.
Joseph J; Nathenson MJ; Trinh VA; Malik K; Nowell E; Carter K; Weathers SP; Demetri GD; Araujo D; Conley AP
J Immunother Cancer; 2019 Nov; 7(1):296. PubMed ID: 31703609
[TBL] [Abstract][Full Text] [Related]
5. IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy.
Kohli K; Yao L; Nowicki TS; Zhang S; Black RG; Schroeder BA; Farrar EA; Cao J; Sloan H; Stief D; Cranmer LD; Wagner MJ; Hawkins DS; Pillarisetty VG; Ribas A; Campbell J; Pierce RH; Kim EY; Jones RL; Riddell SR; Yee C; Pollack SM
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963013
[TBL] [Abstract][Full Text] [Related]
6. NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis.
Lai JP; Robbins PF; Raffeld M; Aung PP; Tsokos M; Rosenberg SA; Miettinen MM; Lee CC
Mod Pathol; 2012 Jun; 25(6):854-8. PubMed ID: 22388761
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade.
Frankiw L; Singh A; Peters C; Comin-Anduix B; Berent-Maoz B; Macabali M; Shammaie K; Quiros C; Kaplan-Lefko P; Baselga Carretero I; Ribas A; Nowicki TS
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37156551
[TBL] [Abstract][Full Text] [Related]
8. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
Robbins PF; Morgan RA; Feldman SA; Yang JC; Sherry RM; Dudley ME; Wunderlich JR; Nahvi AV; Helman LJ; Mackall CL; Kammula US; Hughes MS; Restifo NP; Raffeld M; Lee CC; Levy CL; Li YF; El-Gamil M; Schwarz SL; Laurencot C; Rosenberg SA
J Clin Oncol; 2011 Mar; 29(7):917-24. PubMed ID: 21282551
[TBL] [Abstract][Full Text] [Related]
9. Histological Assessment of Synovial Sarcoma Before and After TCR-T Cell Therapy and Cryoablation: A Case Report.
Asanuma K; Ishihara M; Nakamura T; Uchida K; Hagi T; Kageyama S; Shiku H; Sudo A
Anticancer Res; 2023 Dec; 43(12):5737-5748. PubMed ID: 38030212
[TBL] [Abstract][Full Text] [Related]
10. Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1
D'Angelo SP; Melchiori L; Merchant MS; Bernstein D; Glod J; Kaplan R; Grupp S; Tap WD; Chagin K; Binder GK; Basu S; Lowther DE; Wang R; Bath N; Tipping A; Betts G; Ramachandran I; Navenot JM; Zhang H; Wells DK; Van Winkle E; Kari G; Trivedi T; Holdich T; Pandite L; Amado R; Mackall CL
Cancer Discov; 2018 Aug; 8(8):944-957. PubMed ID: 29891538
[TBL] [Abstract][Full Text] [Related]
11. A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.
Ishihara M; Nishida Y; Kitano S; Kawai A; Muraoka D; Momose F; Harada N; Miyahara Y; Seo N; Hattori H; Takada K; Emori M; Kakunaga S; Endo M; Matsumoto Y; Sasada T; Sato E; Yamada T; Matsumine A; Nagata Y; Watanabe T; Kageyama S; Shiku H
Int J Cancer; 2023 Jun; 152(12):2554-2566. PubMed ID: 36727538
[TBL] [Abstract][Full Text] [Related]
12. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y
Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial.
Kawai A; Ishihara M; Nakamura T; Kitano S; Iwata S; Takada K; Emori M; Kato K; Endo M; Matsumoto Y; Kakunaga S; Sato E; Miyahara Y; Morino K; Tanaka S; Takahashi S; Matsuo F; Matsumine A; Kageyama S; Ueda T
Clin Cancer Res; 2023 Dec; 29(24):5069-5078. PubMed ID: 37792433
[TBL] [Abstract][Full Text] [Related]
14. Current status of engineered T-cell therapy for synovial sarcoma.
Dallos M; Tap WD; D'Angelo SP
Immunotherapy; 2016 Sep; 8(9):1073-80. PubMed ID: 27485079
[TBL] [Abstract][Full Text] [Related]
15. First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient.
Pollack SM; Lu H; Gnjatic S; Somaiah N; O'Malley RB; Jones RL; Hsu FJ; Ter Meulen J
J Immunother; 2017 Oct; 40(8):302-306. PubMed ID: 28891906
[TBL] [Abstract][Full Text] [Related]
16. Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β.
Silk JD; Abbott RJM; Adams KJ; Bennett AD; Brett S; Cornforth TV; Crossland KL; Figueroa DJ; Jing J; O'Connor C; Pachnio A; Patasic L; Peredo CE; Quattrini A; Quinn LL; Rust AG; Saini M; Sanderson JP; Steiner D; Tavano B; Viswanathan P; Wiedermann GE; Wong R; Jakobsen BK; Britten CM; Gerry AB; Brewer JE
J Immunol; 2022 Jan; 208(1):169-180. PubMed ID: 34853077
[TBL] [Abstract][Full Text] [Related]
17. Engineered T Cells in Synovial Sarcoma: Persistence Pays Off!
Keung EZ; Tawbi HA
Cancer Discov; 2018 Aug; 8(8):914-917. PubMed ID: 30076141
[No Abstract] [Full Text] [Related]
18. The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients.
Pollack SM
Expert Rev Vaccines; 2018 Feb; 17(2):107-114. PubMed ID: 29280411
[TBL] [Abstract][Full Text] [Related]
19. Expression of New York esophageal squamous cell carcinoma 1 and its association with Foxp3 and indoleamine-2,3-dioxygenase in microenvironment of nonsmall cell lung cancer.
Wang H; Xia Y; Yu J; Guan H; Wu Z; Ban D; Wang M
HLA; 2019 Jul; 94(1):39-48. PubMed ID: 30953385
[TBL] [Abstract][Full Text] [Related]
20. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.
Trautmann M; Sievers E; Aretz S; Kindler D; Michels S; Friedrichs N; Renner M; Kirfel J; Steiner S; Huss S; Koch A; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Waha A; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
Oncogene; 2014 Oct; 33(42):5006-16. PubMed ID: 24166495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
